Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863996 | 1.00 | IRAK1 (0.36) | IRAK1IRAK4SCN9APIK3CDPIK3R1 | |
| SCHEMBL863650 | 0.82 | IRAK1 (0.39) | IRAK1IRAK4SCN9APIK3CDPIK3R1 | |
| SCHEMBL863649 | 0.82 | IRAK1 (0.39) | IRAK1IRAK4SCN9APIK3CDPIK3R1 | |
| SCHEMBL2113563 | 0.79 | DPP4 (0.36) | SCN9APIK3CDPIK3R1KDM4EIDH1 | |
| SCHEMBL2113571 | 0.79 | DPP4 (0.36) | SCN9APIK3CDPIK3R1KDM4EIDH1 | |
| SCHEMBL2118050 | 0.74 | KRAS (0.39) | KDM4E | |
| SCHEMBL2118042 | 0.74 | KRAS (0.39) | KDM4E | |
| SCHEMBL865373 | 0.71 | IRAK1 (0.39) | IRAK1IRAK4SCN9APIK3CDADORA2A | |
| SCHEMBL865372 | 0.71 | IRAK1 (0.39) | IRAK1IRAK4SCN9APIK3CDADORA2A | |
| SCHEMBL2115845 | 0.69 | DPP4 (0.35) | PIK3CDPIK3R1KDM4EIDH1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | IRAK1 109/4885IRAK4 107/4885SCN9A 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.